drugset / Trial / NCT04301557

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

NCT04301557 ↗

Phase 2 Unknown 25 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also recommended as an alternative choice for unresectable locally advanced colon cancer. Thus, this study will investigate the efficacy and toxicity of combination strategy using PD1 antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal cancer patients.

Timeline

Start
2020-07-31
Primary completion
2024-04-22
Completion
2024-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications